Wystpuje w formie zredukowanej oraz utlenionej, a proporcja midzy tymi postaciami odzwierciedla stan rwnowagi redoks w komrce
C.BrinkmanP.et al (2018)
The modifications made to human GLP-1 include: Amino acid substitutions that resist DPP-4 enzyme degradation Attachment of fatty acid chains (acylation) as seen in semaglutide and liraglutide Fusion with immunoglobulin fragments (as in dulaglutide) to increase molecular size These changes are designed using rational drug design principles and implemented through biotechnology
Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
Carron, Lausanne (Mdecine durgence)
